Similarly, in thyroid carcinoma, we observed an interaction between ERBB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, and four inhibitors (sapitinib, poziotinib, gefitinib, and dacomitinib). Here, EGFR is linked to thyroid gland carcinoma.